A Safety Study in Participants With Advanced Solid Tumors

Inclusion Criteria

• •Participants who have histologically confirmed solid malignancy or lymphoma that is unresectable and/or metastatic for which monotherapy with gemcitabine HCl, docetaxel, temozolomide, cisplatin, or erlotinib would otherwise be appropriate
• •Must have tumor progression after receiving standard/approved chemotherapy or limited treatment options
• •Must have measurable or nonmeasurable disease
• •Have given written informed consent prior to any study-specific procedures
• •Must have adequate hepatic, hematologic and renal function
• •Must have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy or other investigational therapy for at least 4 weeks (6 weeks for mitomycin-C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy. Endocrine therapies for the treatment of prostate cancer may be continued, at the discretion of the investigator. Whole brain radiation must have been completed 90 days before starting study therapy. Participants without evidence of brain metastases who have received prophylactic whole brain irradiation as part of standard of care for small cell lung cancer may be included in the study with a shorter washout period pending approval by the Lilly physician.
• •Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 6 months following the last dose of study drug.
• •Females with child-bearing potential must have had a negative serum pregnancy test within 7 days prior to the first dose of study drug.
• •Must have a serum albumin level greater than or equal to 3.0 g/dL (30 g/L).
• •Must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale